Journal: Scientific Reports

Article Title: Endothelial colony forming cells and mesenchymal progenitor cells form blood vessels and increase blood flow in ischemic muscle

doi: 10.1038/s41598-017-00809-1

Figure Lengend Snippet: Myeloid cells recruited into murine ischemic hind limb muscle after human ECFC + MPC injection. Ischemic hind limb muscles with/without cell injection were harvested, fixed, and sectioned for confocal microscopy analysis. Sections were incubated with biotinylated UEA I followed by Fluorescein-Streptavidin to detect human ECFC (green). After that, sections were incubated with primary antibodies (rat anti-mouse CD11b, rat anti-mouse Ly-6G, or rat anti-mouse F4/80 antibodies) followed by goat anti-rat Alexa Fluor-568 (red). In parallel experimental sets, ischemic hind limb muscles were harvested, digested and analyzed by flow cytometry. ( A ) Representative confocal images of myeloid cells in the ischemic hind limb muscles injected with Matrigel or ECFC + MPC at day 2 and 7 (scale bars represent 50 μm). ( B ) Representative flow cytometry analyses of contralateral hind limb muscles and ischemic hind limb muscles injected with Matrigel or ECFC + MPC at day 2. ( C ) Quantitative cytometric analyses of myeloid lineage cells obtained from ischemic hind limb muscles (n = 3; means ± SEM). ○ Shows cell number obtained from ischemic hind limb muscles injected with Matrigel alone. ● Shows cell number obtained from ischemic hind limb muscles injected with ECFC + MPC in Matrigel. *Significant difference (P ≤ 0.05) between groups. ( D ) Quantitative cytometric analyses of human and murine vascular cells and murine stromal cells obtained from ischemic hind limb muscles at day 0, 2, and 7 (n = 3; means ± SEM). *Significant difference (P ≤ 0.05) between groups.

Article Snippet: Sections were incubated for 1 h with goat anti-rat alexa fluor-568 antibodies (1:100), and mounted with Vectashield with DAPI (Vector).

Techniques: Injection, Confocal Microscopy, Incubation, Flow Cytometry

Journal: Cancer cell

Article Title: Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy

doi: 10.1016/j.ccell.2019.05.001

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: ​ REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies ERK2 Santa Cruz Biotechnology sc-154 Cyclin B1 Santa Cruz Biotechnology sc-245 Cdc2Y15 Cell Signaling Technology 4539 Cleaved Caspase-3 Cell Signaling Technology 9661 FOXM1 Cell Signaling Technology 5436 Cyclin E, clone HE12 Santa Cruz sc-247 Tet R Abcam ab25845 β-actin, clone AC-15 Sigma A3854 Anti-γH2A.X (phospho S140) antibody Abcam ab22551 phospho-Histone H3 (Ser-10) Abcam ab5176 Phospho-Histone H3 (Ser10) (Alexa Fluor® 488) Cell Signaling Technology 3465 Phospho RPA32 (S4/S8) Antibody Bethyl Laboratories A300-245A Anti-p53R2 + RRM2 antibody Abcam ab209995 Anti-BrdU antibody [BU1/75 (ICR1)] Abcam ab6326 Anti-BrdU (B44) BD Biosciences 347580 Goat Anti-Rabbit Alexa Fluor® 488 (IgG H&L) Abcam ab150077 Goat Anti-Mouse Alexa Fluor® 568 (IgG H&L) Abcam ab175471 Goat Anti-Rabbit Alexa Fluor® 568 (IgG H&L) Abcam ab175471 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 647) Abcam ab150079 Goat Anti-mouse IgG H&L (Alexa Fluor® 647) Abcam ab150115 Anti-Mouse IgG, HRP-linked Thermo Fisher Scientific 62-6520 Anti-Rabbit IgG, HRP-linked Thermo Fisher Scientific 65-6120 RPPA antibodies RPPA Core Facility, MD Anderson Cancer Center https://www.mdanderson.org/research/research-resources/corefacilities/functional-proteomics-rppa-core.html Biological Samples Patient Derived Xenografts (PDXs) UT M.D.

Techniques: Derivative Assay, Recombinant, Western Blot, Lysis, Staining, Plasmid Preparation, Sequencing, Software